Compare Adaptive Biotechnologies Corp (ADPT) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs L3Harris Technologies Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.86 (market cap $3.33B), while L3Harris Technologies Inc trades at $291.85 (market cap $55.03B). The key difference: L3Harris Technologies Inc is far larger — about 16.5× Adaptive Biotechnologies Corp's market cap, and L3Harris Technologies Inc pays a 1.69% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | LHX | |
|---|---|---|
Market Cap | $3.33B | $55.03B |
Sector | Health | Industrials |
52-Week High | $22.37 | $378.48 |
52-Week Low | $10.24 | $257.09 |
Enterprise Value | $3.19B | $65.80B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
LHX trades at $295.4, down 2.21% today, with a bullish technical signal despite near-term overbought RSI conditions. The company reported strong Q1 2026 earnings, beating estimates with $5.7B revenue and a 1.4x book-to-bill ratio, boosting its backlog to a record $40.7B. Recent news highlights expansion in missile production and new defense contracts, supporting growth momentum.
LHX presents a favorable outlook with robust defense sector tailwinds and consistent earnings beats, though elevated valuation metrics and geopolitical risks warrant caution. Analyst consensus is strongly bullish with a $367.50 price target, implying significant upside from current levels if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
